Janus Henderson Group’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $141M | Buy |
9,541,270
+2,012,648
| +27% | +$29.8M | 0.07% | 220 |
|
|
2025
Q1 | $148M | Buy |
7,528,622
+3,469,990
| +85% | +$68.3M | 0.08% | 211 |
|
|
2024
Q4 | $70.7M | Buy |
4,058,632
+4,026,819
| +12,658% | +$70.1M | 0.04% | 321 |
|
|
2024
Q3 | $445K | Hold |
31,813
| – | – | ﹤0.01% | 2092 |
|
|
2024
Q2 | $261K | Sell |
31,813
-368
| -1% | -$3.02K | ﹤0.01% | 2267 |
|
|
2024
Q1 | $248K | Buy |
32,181
+1
| +0% | +$8 | ﹤0.01% | 2317 |
|
|
2023
Q4 | $289K | Sell |
32,180
-55
| -0.2% | -$494 | ﹤0.01% | 2255 |
|
|
2023
Q3 | $288K | Sell |
32,235
-6,934,735
| -100% | -$62M | ﹤0.01% | 2202 |
|
|
2023
Q2 | $107M | Buy |
6,966,970
+121,157
| +2% | +$1.86M | 0.07% | 249 |
|
|
2023
Q1 | $154M | Buy |
6,845,813
+1,754,528
| +34% | +$39.5M | 0.1% | 193 |
|
|
2022
Q4 | $107M | Sell |
5,091,285
-2,733,685
| -35% | -$57.5M | 0.08% | 231 |
|
|
2022
Q3 | $193M | Buy |
7,824,970
+3,786,339
| +94% | +$93.3M | 0.07% | 241 |
|
|
2022
Q2 | $97.9M | Sell |
4,038,631
-113,416
| -3% | -$2.75M | 0.07% | 256 |
|
|
2022
Q1 | $107M | Buy |
4,152,047
+135,889
| +3% | +$3.5M | 0.05% | 302 |
|
|
2021
Q4 | $125M | Sell |
4,016,158
-6,916
| -0.2% | -$215K | 0.05% | 313 |
|
|
2021
Q3 | $97.6M | Buy |
4,023,074
+117,961
| +3% | +$2.86M | 0.04% | 367 |
|
|
2021
Q2 | $57M | Sell |
3,905,113
-245,443
| -6% | -$3.58M | 0.02% | 534 |
|
|
2021
Q1 | $104M | Buy |
4,150,556
+67,003
| +2% | +$1.67M | 0.05% | 362 |
|
|
2020
Q4 | $111M | Buy |
4,083,553
+426,396
| +12% | +$11.6M | 0.05% | 336 |
|
|
2020
Q3 | $67.5M | Buy |
3,657,157
+745,088
| +26% | +$13.8M | 0.04% | 419 |
|
|
2020
Q2 | $59.4M | Buy |
2,912,069
+2,752,874
| +1,729% | +$56.2M | 0.03% | 444 |
|
|
2020
Q1 | $2.32M | Buy |
+159,195
| New | +$2.32M | ﹤0.01% | 984 |
|